REG-Arix Bioscience PLC Unaudited NAV for March 2023

Arix BioscienceAnnouncement

17/04/2023 07:15

============

   Arix Bioscience PLC (ARIX)
   Unaudited NAV for March 2023

   17-Apr-2023 / 07:00 GMT/BST

   ══════════════════════════════════════════════════════════════════════════

                                        

                              Arix Bioscience plc

                                        

                          Unaudited NAV for March 2023

    

   LONDON, 17 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE:
   ARIX), a transatlantic  venture capital  company focused  on investing  in
   breakthrough biotechnology companies,  announces the  unaudited Net  Asset
   Value (“NAV”) of the Company for the date ended 31 March 2023 as follows:

    

                                 NAV Breakdown                             
                                                                 Total
       Date       Listed                                Other     NAV    NAV
                 Portfolio Unlisted Portfolio  Cash   Interests          per
                                                                        share
   31 March 2023
                  £42.9m         £66.6m       £108.7m   £3.1m   £221.3m £1.71
    (unaudited)

    

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 1 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    2 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience plc is a transatlantic venture capital company focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCL
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   237106
   EQS News ID:    1608427


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1608427&application_name=news&site_id=refinitiv

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1608427&site_id=refinitiv&application_name=news


============